Goldman Sachs’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Goldman Sachs’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-18,060	Closed	-$43K	–	7123
2021 Q4	$43K	Sell	18,060 -19,089	-51%	-$77.7K	﹤0.01%	6288
2021 Q3	$203K	Buy	37,149 +18,929	+104%	+$117K	﹤0.01%	5722
2021 Q2	$136K	Buy	18,220 +2,837	+18%	+$20.1K	﹤0.01%	5870
2021 Q1	$125K	Buy	15,383 +1,605	+12%	+$17.5K	﹤0.01%	5779
2020 Q4	$125K	Buy	+13,778	New	+$113K	﹤0.01%	5251
2020 Q1	–	Sell	-111,706	Closed	-$561K	–	5664
2019 Q4	$561K	Buy	+111,706	New	+$710K	﹤0.01%	4438
2019 Q2	–	Sell	-49,525	Closed	-$718K	–	5430
2019 Q1	$718K	Buy	+49,525	New	+$682K	﹤0.01%	4241

Other funds holding KLDO

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's KLDO Position: Q1 2022 in Review

Goldman Sachs sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q1 2022, closing a stake of 18,060 shares — an estimated $43K sold.

Goldman Sachs first reported a position in KLDO in Q1 2019 and held it in 7 quarters. The position peaked at $718K in Q1 2019. 63 funds tracked by Wall St. Rank hold KLDO as of Q1 2022.

Goldman Sachs reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Goldman Sachs sold 18,060 Kaleido Biosciences, Inc. Common Stock shares in Q1 2022, an estimated $43K.
Goldman Sachs first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2019 and held it in 7 quarters.
Goldman Sachs's Kaleido Biosciences, Inc. Common Stock position peaked at $718K in Q1 2019.
63 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q1 2022.

Based on Goldman Sachs's 13F filing for Q1 2022, filed 16 May 2022.